Invex Therapeutics Ltd

ASX:IXC (Australia)   Ordinary Shares
A$ 0.09 (-5.56%) Apr 15
At Loss
P/B:
1.22
Market Cap:
A$ 6.76M ($ 4.38M)
Enterprise V:
A$ 612.00K ($ 397.00K)
Volume:
5.62K
Avg Vol (2M):
49.27K
Volume:
5.62K
At Loss
Avg Vol (2M):
49.27K

Business Description

Description
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.84
Interest Coverage No Debt
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 37.19
9-Day RSI 44.24
14-Day RSI 46.73
6-1 Month Momentum % -53.16
12-1 Month Momentum % -80

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.38
Quick Ratio 6.38
Cash Ratio 6.25

Profitability Rank

Name Current Vs Industry Vs History
ROE % -35.2
ROA % -32.82
ROCE % -39.94

Financials

ASX:IXC's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Invex Therapeutics Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$)
EPS (TTM) (A$) -0.08
Beta 1.12
Volatility % 61.54
14-Day RSI 46.73
14-Day ATR (A$) 0.002653
20-Day SMA (A$) 0.08725
12-1 Month Momentum % -80
52-Week Range (A$) 0.06 - 0.63
Shares Outstanding (Mil) 75.15

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Invex Therapeutics Ltd Filings

Filing Date Document Date Form
No Filing Data

Invex Therapeutics Ltd Stock Events

Financials Calendars
Event Date Price(A$)
No Event Data

Invex Therapeutics Ltd Frequently Asked Questions

What is Invex Therapeutics Ltd(ASX:IXC)'s stock price today?
The current price of ASX:IXC is A$0.09. The 52 week high of ASX:IXC is A$0.63 and 52 week low is A$0.06.
When is next earnings date of Invex Therapeutics Ltd(ASX:IXC)?
The next earnings date of Invex Therapeutics Ltd(ASX:IXC) is .
Does Invex Therapeutics Ltd(ASX:IXC) pay dividends? If so, how much?
The  Dividend Yield %  of Invex Therapeutics Ltd(ASX:IXC) is 207% (As of Today), Highest Dividend Payout Ratio of Invex Therapeutics Ltd(ASX:IXC) was 0. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Invex Therapeutics Ltd(ASX:IXC) is 207%. For more information regarding to dividend, please check our Dividend Page.

Press Release

Subject Date
No Press Release